SCHEMBL1934445

SCHEMBL1934445

CSc1cc(O)n2nccc2n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 1/20 0.40
PRKAA1 Q13131 2/20 0.34
PRKAB2 O43741 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA2 P54646 1/20 0.34
PRKAG3 Q9UGI9 1/20 0.34
PRKAG2 Q9UGJ0 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34
CCNT1 O60563 8/20 0.33
CDK9 P50750 8/20 0.33
GSK3B P49841 2/20 0.32
PIM1 P11309 2/20 0.31
KCNN3 Q9UGI6 2/20 0.31
PIM3 Q86V86 1/20 0.31
PLK3 Q9H4B4 1/20 0.31
PIM2 Q9P1W9 1/20 0.31
DPP4 P27487 1/20 0.31
AURKA O14965 1/20 0.31
JAK2 O60674 1/20 0.31
NTRK1 P04629 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12363999 0.79 PDE10A (0.61) PDE10ACCNT1CDK9KCNN3KCNN1
SCHEMBL4102510 0.77 PDE10A (0.43) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL31023 0.76 PDE10A (0.46) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL30603250 0.73 DYRK1A (0.43) PDE10ACCNT1CDK9CDK5MAPK14
SCHEMBL16828091 0.73 PDE10A (0.43) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL12364000 0.73 PDE10A (0.43) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL7431490 0.72 PRKAB2 (0.54) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL1071726 0.70 PDE10A (0.37) PDE10APRKAA1PRKAB2PRKAG1PRKAA2
SCHEMBL30443263 0.70 CCR1 (0.47) PDE10AKCNN3KDRMAPK14CDK2
SCHEMBL23933214 0.70 CDK7 (0.49) PDE10APRKAA1PRKAB2PRKAG1PRKAA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8518931-B2 Compounds and compositions as kinase inhibitors IRM LLC (BM) 2013-08-27 US disclosed
EP-2509602-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-10-17 EP disclosed
US-20110190264-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS IRM LLC (BM) 2011-08-04 US disclosed
WO-2011068667-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS CK2 INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190264-A1 COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS ROS1, IGF1R, INSR PDE10A 2751/4885PRKAA1 340/4885PRKAB2 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.